Maat Pharma SA Market Cap ($22.27 Million)
Market Cap & Net Worth: Maat Pharma SA (MAAT)
Maat Pharma SA market cap. Maat Pharma SA (PA:MAAT) has a market capitalization of $22.27 Million (€19.05 Million) as of November 5, 2026. Listed on the PA stock exchange, this France-based company holds position #24596 globally and #393 in its home market, demonstrating a -4.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Maat Pharma SA's stock price €1.02 by its total outstanding shares 18751521 (18.75 Million). Also see Maat Pharma SA operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Maat Pharma SA Market Cap History (2021–2026)
Maat Pharma SA market cap history from 2021 to 2026. Data shows change from $292.67 Million to $22.27 Million (-40.85% CAGR). Check MAAT live share price for real-time trading data and today's change.
Index Memberships
Maat Pharma SA is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Health Care
FRHC
|
$262.98 Billion | 0.01% | #28 of 36 |
Weight: Maat Pharma SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Maat Pharma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Maat Pharma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MAAT shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
54.26x
Maat Pharma SA's market cap is 54.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $292.67 Million | $972.00K | -$9.02 Million | 301.10x | N/A |
| 2022 | $175.38 Million | $1.43 Million | -$13.71 Million | 122.64x | N/A |
| 2023 | $153.02 Million | $2.23 Million | -$19.72 Million | 68.68x | N/A |
| 2024 | $174.50 Million | $3.22 Million | -$28.90 Million | 54.26x | N/A |
Competitor Companies of MAAT by Market Capitalization
Companies near Maat Pharma SA in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Maat Pharma SA for a full breakdown of the balance sheet.
Key companies related to Maat Pharma SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Maat Pharma SA (2021–2026)
Market capitalization of Maat Pharma SA from 2021 to today. Between 2021 and today, Maat Pharma SA's market cap moved from $292.67 Million to $ 22.27 Million, with a yearly change of -40.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €22.27 Million | -78.88% |
| 2025 | €105.45 Million | -39.57% |
| 2024 | €174.50 Million | +14.04% |
| 2023 | €153.02 Million | -12.75% |
| 2022 | €175.38 Million | -40.07% |
| 2021 | €292.67 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Maat Pharma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.27 Million USD |
| MoneyControl | $22.27 Million USD |
| MarketWatch | $22.27 Million USD |
| marketcap.company | $22.27 Million USD |
| Reuters | $22.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more